National Comprehensive Cancer Network



Educational Events & Programs

The article will publish in the spring of 2017.

On Friday, September 16, 2016, the National Comprehensive Cancer Network® (NCCN®) hosted the NCCN Policy Summit: Developments in Biosimilars and Molecular Testing in Washington, D.C.

The Policy summit provided health care providers, government and regulatory organizations, patients and patient advocacy groups, pharmaceuticals, biotech and diagnostic companies, payers, pharmacy benefit managers, and other relevant stakeholders with a forum to discuss issues and opportunities related to biosimilars and molecular testing.

If you have any questions about the NCCN Policy Summit Series, please contact Katy Winckworth-Prejsnar.

This activity is supported by an educational donation provided by Amgen. Supported by AmerisourceBergen; Apobiologix, a division of ApoPharma USA, Inc.; Astellas; EMD Serono; Genentech, a Member of the Roche Group; Genomic Health; Gilead Sciences, Inc.; HELSINN; Incyte Corporation; Janssen Oncology; Medivation, Inc.; Nanostring; Pharmacyclics LLC, An AbbVie Company; and Teva Oncology. Sponsored by AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; and Mylan. Supported by an unrestricted educational grant provided by Hologic. Supported by a grant from ImmunoGen, Inc. Sponsored in part by Mylan. Supported by an independent educational grant from Merck & Co., Inc.